Status
Conditions
Treatments
About
Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment.
Arterial contrast ("spot sign") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis.
An equivalent marker has also been described in gadolinium-enhanced MRI.
By studying the radiological appearance of gadolinium "spot signs" on MRI, which has better parenchymal resolution, the researchers propose to retrace the phenomenology of the acute phase of cerebral hemorrhage in order to better estimate the risk of radiological aggravation by subgroup, which could serve as a target population for future therapeutic trials.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
128 participants in 1 patient group
Loading...
Central trial contact
Teodora PARVU
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal